EcoR1 Capital’s Rubius Therapeutics, Inc RUBY Stock Holding History

EcoR1 Capital’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-525,877	Closed	-$5M	–	64
2019 Q4	$5M	Buy	525,877 +265,725	+102%	+$2.57M	0.45%	34
2019 Q3	$2.04M	Sell	260,152 -203,000	-44%	-$2.37M	0.26%	30
2019 Q2	$7.29M	Sell	463,152 -183,076	-28%	-$2.95M	0.74%	24
2019 Q1	$11.7M	Buy	646,228 +54,100	+9%	+$830K	1.08%	26
2018 Q4	$9.52M	Hold	592,128	–	–	0.95%	33
2018 Q3	$14.2M	Buy	+592,128	New	+$13.5M	1.28%	24

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

EcoR1 Capital's RUBY Position: Q1 2020 in Review

EcoR1 Capital sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2020, closing a stake of 525,877 shares — an estimated $5M sold.

EcoR1 Capital first reported a position in RUBY in Q3 2018 and held it in 6 quarters. The position peaked at $14.2M in Q3 2018. 76 funds tracked by Wall St. Rank hold RUBY as of Q1 2020.

EcoR1 Capital reported no remaining Rubius Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
EcoR1 Capital sold 525,877 Rubius Therapeutics, Inc shares in Q1 2020, an estimated $5M.
EcoR1 Capital first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 6 quarters.
EcoR1 Capital's Rubius Therapeutics, Inc position peaked at $14.2M in Q3 2018.
76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2020.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.